Novartis says Cosentyx could be used as an early intervention in psoriasis after new data suggests it is the first drug of its kind to modify the course of the disease. The Swiss big pharma ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Medically reviewed by Brendan Camp, MD Hidradenitis suppurativa (HS) is a chronic (long-term) condition that causes painful ...

Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S.

Secukinumab is under clinical development by Novartis and currently in Phase II for Unspecified Dermatological Disorders.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

INR:1868. clt frozenfluffies Novartis Cosentyx first-line treatment: rapid and powerful clearance of skin lesions and improved quality of life Puli Pharmaceuti ...